Archive: 12/12/2019
Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer
Neoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to multi-agent chemotherapy in patients with high-risk luminal B breast cancer, ...
Dec 12, 2019